article thumbnail

Novel Tricuspid Valve Procedure Improves Patients' Quality of Life and Health Status

DAIC

milla1cf Fri, 06/21/2024 - 20:10 June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using the Edwards EVOQUE system. by the Food and Drug Administration.

Tricuspid 105
article thumbnail

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

DAIC

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100
article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid 102
article thumbnail

The Society of Thoracic Surgeons Launches New Valve Surgery Risk Calculators

DAIC

Tricuspid Valve Repair Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results. Analysis of 13,587 patients undergoing isolated tricuspid valve surgery from 2017 to 2023 revealed a 5.5%

TAVR 111
article thumbnail

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

DAIC

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for most patients with TR.

article thumbnail

2023 STS Coding Workshop

Society of Thoracic Surgeons - Allied Health

Event 2023 STS Coding Workshop kchalko Tue, 11/15/2022 - 16:12 Event dates Feb 10–11, 2023 Location Virtual Registrants : To access the library of on-demand content, log into the STS Learning Center. Then go to “In Progress” courses on the dashboard or look in the “My Activities” tab. Missed the event? STS Members receive a discount!

article thumbnail

Distribution Variance of Focal Atrial Tachycardia Foci and Long‐Term Outcomes After Ablation: Experience From Two Chinese Centers

Journal of Cardiovascular Electrophysiology

Methods and Results A total of 323 consecutive FAT patients who underwent electrophysiological study and radiofrequency catheter ablation between January 2011 and March 2023 were selected for this study. Young adults had a higher proportion of FAT originating from the superior vena cava and pulmonary veins. After a mean follow-up of 47.2